TP53 and prostate cancer: MDM2 is a negative regulator of TP53 by mediating TP53's degradation 30, and its amplification has been identified in a variety of cancers at a frequency of ~3%, which might have a potential role in treatment resistance of prostate cancer, neuroblastoma and lung cancer 31-33.